Research in IMO
iPS cells as a study tool and model to implement the CRISPR-CAS system in the treatment of Retinal Dystrophies
The ultimate goal of this research is to lay the foundation for the application of cell therapy in the treatment of retinal dystrophies, by implanting healthy cells, obtained from iPS cells, in the patients' affected tissues.
Evaluation of Ocular Surface Disease Syntoms and Patients Satisfaction with Thealoz Duo after 84 days of Daily treatment
A study desease progression in genetically define subjects with geographic atrophy secondary to Age-Related Macular Degeneration
Mass sequencing of exomes for the identification of new genes and variants responsible for retinal dystrophies
Retinitis pigmentosa, with a prevalence of 1 in 4,000 people and more than one million sufferers worldwide, is the most common retinal dystrophy. These diseases are neurodegenerative and caused by the death of the photoreceptors and cells of the retinal pigment epithelium.
An open-label, randomized, active-controlled, parallel-group, Phase-3b study of the efficacy, safety, and tolerability of three different treatment regimens of 2 mg aflibercept administered by intravitreal injections to subjects with diabetic macular edema (DME)